RESEARCH NOTICE & LEGAL DISCLAIMER

FOR RESEARCH PURPOSES ONLY. All information provided within the Biolabs Peptides Research Centre is intended strictly for scientific, laboratory, and educational purposes.

Not Medical Advice: The protocols and data presented herein do not constitute medical advice, nursing advice, or a professional healthcare diagnosis.
Non-Therapeutic: These peptides are not intended to diagnose, treat, cure, or prevent any medical condition or disease.
Researcher Responsibility: Any research conducted should be performed by qualified professionals in a controlled laboratory environment. By accessing this data, you acknowledge that you are responsible for following your local laws and institutional safety guidelines.

GLOW

70MG

SHOP VIALS

SHOP PRE-FILLED PEN

HIGHLIGHTS

The GLOW blend is a high-potency regenerative trifecta combining GHK-Cu, TB-500 (Thymosin Beta-4 fragment), and BPC-157. This 70mg vial is engineered for comprehensive tissue repair, systemic anti-inflammation, and accelerated wound healing. By merging three of the most effective "repair" peptides into a single solution, the GLOW blend offers researchers a synergistic tool to study deep dermal remodeling, tendon/ligament recovery, and localized site-specific healing simultaneously.

Observed Benefits

Synergistic Repair Signaling: Combines collagen synthesis (GHK-Cu) with cell migration (TB-500) and localized growth factor upregulation (BPC-157).
Accelerated Wound Healing: Observed in research to significantly speed up wound contraction and skin re-epithelialization.
Deep Tissue Recovery: Studied for its ability to repair tendons, ligaments, and muscle tissue more effectively than single-peptide protocols.
Reduced Fibrosis: TB-500 and BPC-157 work together to minimize scar tissue formation, promoting more organized and functional tissue repair.
Anti-Inflammatory Action: Lowers pro-inflammatory cytokines while protecting cells from oxidative stress.

Protocol Overview

Research involving the GLOW blend utilizes subcutaneous administration. A 70mg vial is typically reconstituted with 3.0 mL of Bacteriostatic Water, resulting in a highly concentrated solution of approximately 23.3 mg per mL. Because this blend includes GHK-Cu, the liquid will have a notable blue tint. Standard research cycles usually run for 4 weeks followed by a rest period to evaluate cumulative progress.

Research Protocol Dosing

Standard Research Dose (Weeks 1–4): 2,330 mcg (10 units on a U-100 syringe) — Inject once daily.

Per-Injection Breakdown: Each 10-unit dose delivers approximately 1.7 mg of GHK-Cu, 0.33 mg of TB-500, and 0.33 mg of BPC-157.

Cycle Duration: 4 weeks of daily administration followed by a 2–4 week "washout" period to assess tissue response before initiating a second cycle.

Syringe Tip: Use a 30-unit (0.3 mL) insulin syringe for maximum precision when measuring the 10-unit dose.

Supplies Needed

Biolabs Peptides GLOW Blend: 70mg Lyophilized Vial.
Reconstitution Liquid: 3.0 mL of Bacteriostatic Water.
Syringes: U-100 Precision Insulin Syringes (0.3 mL or 0.5 mL capacity recommended).
Prep: Alcohol swabs for vial and research site sterilization.

Storage

Pre-reconstitution (Lyophilized Powder): Store frozen at -20°C (-4°F) for long-term stability (up to 2 years).
Post-reconstitution (Liquid Solution): Refrigerate at 2–8°C (36–46°F) at all times. Use within 28 days for optimal potency. Protect from light by storing in an amber vial or wrapping in foil. Do not shake.